Personalized mRNA vaccine plus pembrolizumab cuts melanoma recurrence in phase 3
In a randomized phase 3 trial of 1,137 patients with resected high-risk melanoma, adding an individualized neoantigen mRNA therapy to pembrolizumab improved recurrence-free and distant-metastasis-free survival.
Detailed results from INTerpath-001, a phase 3, double-blind adjuvant trial in patients with completely resected stage IIB to IV cutaneous melanoma, were first presented at the European Society for Medical Oncology (ESMO) Congress in Madrid in October 2026 (abstract LBA1). Merck and Moderna had announced on 19 August 2026 that the trial met its endpoints. The New England Journal of Medicine published the full paper on 11 November 2026. A total of 1,137 patients were randomly assigned 2:1 to individualized neoantigen therapy intismeran autogene plus pembrolizumab, or to placebo plus pembrolizumab.
At a median follow-up of 24.6 months, 24-month recurrence-free survival was 82.2% with the combination and 70.0% with pembrolizumab alone (P<0.001). Overall, the risk of recurrence or death was 42% lower (hazard ratio 0.58; 95% CI, 0.45 to 0.75). Distant-metastasis-free survival at 24 months was 88.5% versus 80.2% (P=0.002). The recurrence benefit was not apparent in the first six months: a piecewise hazard ratio was 0.99 (95% CI, 0.66 to 1.49) before six months and 0.42 (95% CI, 0.30 to 0.58) after six months. Adverse events of grade 3 or higher occurred in 23.6% of patients in the combination group and 20.3% in the control group. Eight patients (1.1%) in the combination group died from an adverse event; five of those deaths occurred before intismeran was administered.
This is a phase 3 adjuvant trial in one cancer setting, and follow-up is still ongoing. Intismeran autogene is a patient-specific mRNA therapy designed to train immune cells against neoantigens from that person's tumor; it was given with pembrolizumab, a standard checkpoint inhibitor used after surgery in high-risk melanoma. Overall-survival data are not yet mature, so the results do not establish a survival benefit, and they should not be read as guidance for individual care. Intismeran is investigational and not approved.
Why it matters
This is a large, randomized phase 3 test of a patient-specific mRNA neoantigen vaccine on top of standard adjuvant immunotherapy. The reduction in recurrence and distant metastasis after six months is a concrete clinical signal, measured against pembrolizumab alone rather than against no adjuvant treatment.
Looking ahead (speculative)
Regulators and the wider field will look next at longer follow-up, including overall survival, and at whether a similar approach helps in other tumors. Those questions are not answered by this melanoma trial.
This is news, not medical advice.
Sources
Sources
- Long et al., Intismeran autogene plus pembrolizumab for resected stage IIB to IV melanoma, New England Journal of Medicine, 11 November 2026
- Merck and Moderna news release, 22 October 2026
- Merck and Moderna news release, 19 August 2026
- INTerpath-001 on ClinicalTrials.gov, NCT05933577
- INTerpath-001 data detail survival, subgroup, and safety findings in melanoma, Cancer Network, 24 October 2026